Cargando…

High-throughput single-сell sequencing in cancer research

With advances in sequencing and instrument technology, bioinformatics analysis is being applied to batches of massive cells at single-cell resolution. High-throughput single-cell sequencing can be utilized for multi-omics characterization of tumor cells, stromal cells or infiltrated immune cells to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Qingzhu, Chu, Han, Jin, Zheng, Long, Haixia, Zhu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065032/
https://www.ncbi.nlm.nih.gov/pubmed/35504878
http://dx.doi.org/10.1038/s41392-022-00990-4
_version_ 1784699495815053312
author Jia, Qingzhu
Chu, Han
Jin, Zheng
Long, Haixia
Zhu, Bo
author_facet Jia, Qingzhu
Chu, Han
Jin, Zheng
Long, Haixia
Zhu, Bo
author_sort Jia, Qingzhu
collection PubMed
description With advances in sequencing and instrument technology, bioinformatics analysis is being applied to batches of massive cells at single-cell resolution. High-throughput single-cell sequencing can be utilized for multi-omics characterization of tumor cells, stromal cells or infiltrated immune cells to evaluate tumor progression, responses to environmental perturbations, heterogeneous composition of the tumor microenvironment, and complex intercellular interactions between these factors. Particularly, single-cell sequencing of T cell receptors, alone or in combination with single-cell RNA sequencing, is useful in the fields of tumor immunology and immunotherapy. Clinical insights obtained from single-cell analysis are critically important for exploring the biomarkers of disease progression or antitumor treatment, as well as for guiding precise clinical decision-making for patients with malignant tumors. In this review, we summarize the clinical applications of single-cell sequencing in the fields of tumor cell evolution, tumor immunology, and tumor immunotherapy. Additionally, we analyze the tumor cell response to antitumor treatment, heterogeneity of the tumor microenvironment, and response or resistance to immune checkpoint immunotherapy. The limitations of single-cell analysis in cancer research are also discussed.
format Online
Article
Text
id pubmed-9065032
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90650322022-05-04 High-throughput single-сell sequencing in cancer research Jia, Qingzhu Chu, Han Jin, Zheng Long, Haixia Zhu, Bo Signal Transduct Target Ther Review Article With advances in sequencing and instrument technology, bioinformatics analysis is being applied to batches of massive cells at single-cell resolution. High-throughput single-cell sequencing can be utilized for multi-omics characterization of tumor cells, stromal cells or infiltrated immune cells to evaluate tumor progression, responses to environmental perturbations, heterogeneous composition of the tumor microenvironment, and complex intercellular interactions between these factors. Particularly, single-cell sequencing of T cell receptors, alone or in combination with single-cell RNA sequencing, is useful in the fields of tumor immunology and immunotherapy. Clinical insights obtained from single-cell analysis are critically important for exploring the biomarkers of disease progression or antitumor treatment, as well as for guiding precise clinical decision-making for patients with malignant tumors. In this review, we summarize the clinical applications of single-cell sequencing in the fields of tumor cell evolution, tumor immunology, and tumor immunotherapy. Additionally, we analyze the tumor cell response to antitumor treatment, heterogeneity of the tumor microenvironment, and response or resistance to immune checkpoint immunotherapy. The limitations of single-cell analysis in cancer research are also discussed. Nature Publishing Group UK 2022-05-03 /pmc/articles/PMC9065032/ /pubmed/35504878 http://dx.doi.org/10.1038/s41392-022-00990-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Jia, Qingzhu
Chu, Han
Jin, Zheng
Long, Haixia
Zhu, Bo
High-throughput single-сell sequencing in cancer research
title High-throughput single-сell sequencing in cancer research
title_full High-throughput single-сell sequencing in cancer research
title_fullStr High-throughput single-сell sequencing in cancer research
title_full_unstemmed High-throughput single-сell sequencing in cancer research
title_short High-throughput single-сell sequencing in cancer research
title_sort high-throughput single-сell sequencing in cancer research
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065032/
https://www.ncbi.nlm.nih.gov/pubmed/35504878
http://dx.doi.org/10.1038/s41392-022-00990-4
work_keys_str_mv AT jiaqingzhu highthroughputsinglesellsequencingincancerresearch
AT chuhan highthroughputsinglesellsequencingincancerresearch
AT jinzheng highthroughputsinglesellsequencingincancerresearch
AT longhaixia highthroughputsinglesellsequencingincancerresearch
AT zhubo highthroughputsinglesellsequencingincancerresearch